Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Lexeo Therapeutics (LXEO) Net Income towards Common Stockholders (2022 - 2026)

Lexeo Therapeutics' Net Income towards Common Stockholders history spans 2 years, with the latest figure at -$14.2 million for Q4 2023.

  • On a quarterly basis, Net Income towards Common Stockholders rose 2.68% to -$14.2 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$66.4 million, a N/A change, with the full-year FY2025 number at -$103.2 million, down 4.97% from a year prior.
  • Net Income towards Common Stockholders hit -$14.2 million in Q4 2023 for Lexeo Therapeutics, up from -$20.1 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for LXEO hit a ceiling of -$13.4 million in Q2 2023 and a floor of -$20.1 million in Q3 2023.